Completed PHASE1 INTERVENTIONAL 3-arm NCT05747573

A Study to Compare Pharmacokinetics of GB1211

An Open-label, Randomized, Three-period, Crossover Study to Compare the Pharmacokinetics of GB1211 Upon Dosing a Capsule Under Fasting Condition and a Tablet Under Fasting and Fed Conditions in Healthy Volunteers

Sponsor: Galecto Biotech AB

Conditions Pharmacokinetics

Interventions GB1211

Updated 6 times since 2023 Last updated: Aug 31, 2023 Started: Jan 3, 2023 Primary completion: Apr 10, 2023 Completion: Apr 10, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05747573, this PHASE1 trial focuses on Pharmacokinetics and remains completed. Sponsored by Galecto Biotech AB, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE1
Apr 2023 — Jun 2023 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 1 earlier version

Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galecto Biotech AB
QPS Holdings LLC

Data source: Galecto Biotech AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands